Author of

• 10692

  +

  P1.08 - Poster Session 1 - Radiotherapy (ID 195)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Radiation Oncology + Radiotherapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 10712

    +

    P1.08-020 - Stereotactic Ablative Radiotherapy for Pulmonary Oligometastasis from Hepatocellular Carcinoma (ID 2503)

    09:30 - 09:30  |  Author(s): S.S. Kim
    • Abstract

    Background
    Stereotactic ablative Radiotherapy (SABR) is a safe and effective treatment modality for primary or metastatic lung cancer. Despite its no great difference in response by pathology according to known publications, there is few report for pulmonary oligometastasis (PM) from hepatocellular carcinoma (HCC). We conducted this study to evaluate treatment outcomes of the SABR for PM from HCC under primary control.

    Methods
    We reviewed the records of patients with PM from HCC who received SABR for metastatic lesion from January 2006 to December 2011. Thirty-seven patients were included for analysis and total number of metastatic lesions was 52. SABR dose was 45, 48 or 60Gy in 3 or 4 fractions. Patients were evaluated by chest and liver dynamic CT scan at 1 and 3 months after completion of SBRT and followed up regularly thereafter.

    Results
    Median follow-up time was 19.9 months (range 6.1-33.6). The complete response (CR) rate was 38.0%. The local progression free survival (LPFS) rate was 92.1% and 88.7% at 1 and 3 years, and mean LPFS time was 69.9±3.6 months. Survival rates at 1 and 3 years were 52.1% and 33.5% in DFS, 67.6% and 35.5% in OS, respectively. Median survival time was 13.6 months (95% CI; 3.9-23.4) in DFS and 19.9 months (95% CI; 6.1-33.6) in OS. Only the initial treatment modality of primary HCC was significant factor in OS from univariate and multivariate analysis, and hazard ratio was 2.70 (95% CI: 1.04-6.96, p=0.040). There was no significant SABR-related acute or chronic complication.

    Conclusion
    SABR for pulmonary oligometastasis from HCC showed good local tumor control equal to the result in primary lung cancer. Patient with pulmonary oligometastasis from HCC can be treated without complication by SABR and assured good quality of life